Mario Contreraz named administrator of IU cancer center clinical trials office

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mario Contreraz was named administrator of the Indiana University Melvin and Bren Simon Cancer Center’s Clinical Trials Office.

As administrator, Contreraz will provide overall direction for the strategy and vision for the Clinical Trials Office to ensure all NCI criteria and guidelines are met. He will also serve as a liaison between the administrative staff and the sponsors, collaborators, and regulatory agencies.

Contreraz had served as interim administrator for the Clinical Trials Office during the recruitment process. He initially joined the Clinical Trials Office in May 2016 as the research nurse administrator.

Prior to joining the CTO, Contreraz was a clinical research manager at the IU School of Medicine’s clinical research center, a clinical research nurse at the Krannert Institute of Cardiology, a nursing associate at Eli Lilly and Company, and an ER nurse at Eskenazi Health. He holds both a master’s of nurse administration, a master’s of business administration from Anderson University, and a bachelor’s degree in nursing from Ball State University.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login